Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Maintenance in MDS/AML after HSCT
NCT00720850Phase 2Terminated
- Sponsor
- Technische Universität Dresden
- Start
- Apr 2008
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Technische Universität Dresden. Primary endpoint: Cumulative incidence of relapse rate at 1 year. Started Apr 2008; status: terminated.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00720850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00720850.